Frazier Life Sciences Management’s Krystal Biotech KRYS Stock Holding History

Frazier Life Sciences Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$179M	Hold	481,307	–	–	3.9%	7
2026 Q1	$124M	Sell	481,307 -7,153	-1%	-$1.9M	3.2%	9
2025 Q4	$120M	Sell	488,460 -200,000	-29%	-$42.1M	3.23%	9
2025 Q3	$122M	Hold	688,460	–	–	3.64%	7
2025 Q2	$94.6M	Hold	688,460	–	–	3.78%	7
2025 Q1	$124M	Sell	688,460 -100,000	-13%	-$16.8M	5.67%	6
2024 Q4	$124M	Sell	788,460 -200,000	-20%	-$35.5M	5.13%	4
2024 Q3	$180M	Hold	988,460	–	–	7.21%	4
2024 Q2	$182M	Hold	988,460	–	–	8.49%	3
2024 Q1	$176M	Hold	988,460	–	–	7.42%	2
2023 Q4	$123M	Hold	988,460	–	–	6.56%	4
2023 Q3	$115M	Sell	988,460 -1,800	-0.2%	-$220K	7.62%	3
2023 Q2	$116M	Buy	990,260 +44,853	+5%	+$4.58M	6.94%	5
2023 Q1	$75.7M	Sell	945,407 -54,330	-5%	-$4.27M	5.48%	7
2022 Q4	$79.2M	Sell	999,737 -18,651	-2%	-$1.38M	4.92%	8
2022 Q3	$71M	Sell	1,018,388 -77,019	-7%	-$5.56M	5.47%	7
2022 Q2	$71.9M	Buy	1,095,407 +229,157	+26%	+$14.3M	6.79%	3
2022 Q1	$57.6M	Buy	+866,250	New	+$54.1M	4.91%	5

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Frazier Life Sciences Management's KRYS Position: Q2 2026 in Review

Frazier Life Sciences Management held its Krystal Biotech (KRYS) position steady in Q2 2026 at 481,307 shares worth $179M. The position accounts for 3.9% of the portfolio, ranked #7.

Frazier Life Sciences Management first reported a position in KRYS in Q1 2022 and has held it in 18 quarters since. The position peaked at $182M in Q2 2024. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Frazier Life Sciences Management held 481,307 shares of Krystal Biotech worth $179M as of Q2 2026.
Frazier Life Sciences Management left its Krystal Biotech share count unchanged in Q2 2026.
Krystal Biotech made up 3.9% of Frazier Life Sciences Management's portfolio in Q2 2026, its #7 holding.
Frazier Life Sciences Management first reported a position in Krystal Biotech in Q1 2022 and has held it in 18 quarters since.
Frazier Life Sciences Management's Krystal Biotech position peaked at $182M in Q2 2024.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.